文献速递前列腺癌

原发局限性前列腺癌患者接受高强度聚焦超声局灶或半侧消融的大队列中期肿瘤学结局

Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer.
PubMed 文献 · BJU Int · 2019-03-18

这项多中心队列研究评估了1032例原发局限性前列腺癌患者接受局灶或半侧高强度聚焦超声(HIFU)消融后的中期肿瘤学结局。中位随访36个月,24、60、96个月总生存率分别为99%、97%、97%,无活检失败生存率分别为84%、64%、54%,无进一步治疗生存率分别为85%、59%、46%,无根治性治疗生存率分别为98%、91%、81%。作者认为局灶HIFU是可行的治疗策略,近十年5年再治疗率下降。

要点

  • 1032例原发局限性前列腺癌患者接受局灶或半侧HIFU消融,中位随访36个月。
  • 24、60、96个月总生存率分别为99%、97%、97%,无根治性治疗生存率分别为98%、91%、81%。
  • 作者认为局灶HIFU是可行治疗策略,再局灶治疗的功能与肿瘤学结局尚待评估。

核心结论

  • 作者认为局灶HIFU治疗前列腺癌是可行的治疗策略,生存和肿瘤学结果可接受,且近十年5年再治疗率下降。
  • 作者指出再次局灶治疗是可行技术,其功能与肿瘤学结局仍有待评估。

研究设计与样本

  • 在两个中心由六位治疗医生连续治疗的原发局限性前列腺癌患者队列,接受局灶消融或半侧消融(Sonablate 500)。
  • 共纳入2005年11月至2017年10月治疗的1032例男性,中位年龄65岁,中位前列腺特异性抗原7 ng/mL。
  • 80.3%的患者Gleason评分≥3+4,中位随访36个月(四分位距14-64个月)。

主要发现

  • 24、60、96个月总生存率分别为99%、97%、97%。
  • 无活检失败生存率(无Gleason 3+4病变)在24、60、96个月分别为84%、64%、54%。
  • 无任何进一步治疗生存率在24、60、96个月分别为85%、59%、46%;接受再治疗的患者中约70%接受了第二次局灶治疗。
  • 无根治性治疗生存率在24、60、96个月分别为98%、91%、81%。
  • 研究期间,接受局灶HIFU的Gleason 3+4病变和多参数磁共振成像定义的T2期病变患者比例增加,首次治疗后5年内再治疗比例随时间下降。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report medium-term oncological outcomes in men receiving primary focal treatment with high-intensity focused ultrasonography ( HIFU) for prostate cancer (PCa). PATIENTS AND METHODS: Consecutive patients with PCa treated with primary focal HIFU at two centres by six treating clinicians were assessed. Patients were submitted to either focal ablation or hemi-ablation using HIFU (Sonablate 500). The primary objective of the study was to assess medium-term oncological outcomes, defined as overall survival, freedom from biopsy failure, freedom from any further treatment and freedom from radical treatment after focal HIFU. The secondary objective was to evaluate the changes in pathological features among patients treated with focal HIFU over time. We also assessed the relationship between year of surgery and 5-year retreatment probability. RESULTS: A total of 1032 men treated between November 2005 and October 2017 were assessed. The median age was 65 years and median prostate-specific antigen level was 7 ng/mL. The majority of patients had a Gleason score of 3 + 4 or above (80.3%). The median (interquartile range) follow-up was 36 (14-64) months. The overall survival rates at 24, 60 and 96 months were 99%, 97% and 97%, respectively. Freedom from biopsy failure, defined as absence of Gleason 3 + 4 disease, was 84%, 64% and 54% at 24, 60 and 96 months. Freedom from any further treatment was 85%, 59% and 46% at 24, 60 and 96 months, respectively. Approximately 70% of patients who were retreated received a second focal treatment. Freedom from radical treatment was 98%, 91% and 81% at 24, 60 and 96 months. During the study period, we observed an increase in the proportion of patients undergoing focal HIFU with Gleason 3 + 4 disease and with T2 stage disease as defined by multiparametric magnetic resonance imaging. Finally, there was a reduction over time in the proportion of patients undergoing re-treatment within 5 years of first treatment. CONCLUSIONS: Focal HIFU for PCa is a feasible therapeutic strategy, with acceptable survival and oncological results and a reduction in the 5-year retreatment rates over the last decade. Re-do focal treatment is a feasible technique whose functional and oncological outcomes have still to be evaluated.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Stabile A, Orczyk C, Hosking-Jervis F, et al. Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer. BJU Int. 2019. PMID: 30753756. doi:10.1111/bju.14710

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。